BRISTOL-MYERS SQUIBB FDA Approval NDA 206843

NDA 206843

BRISTOL-MYERS SQUIBB

FDA Drug Application

Application #206843

Documents

Letter2015-07-28
Letter2016-02-09
Letter2016-02-09
Label2015-07-30
Label2016-02-25
Label2016-04-14
Review2015-08-28
Letter2016-02-09
Label2016-02-25
Label2016-02-25
Summary Review2016-03-03
Summary Review2016-03-03
Review2016-08-24
Review2016-08-24
Letter2017-02-15
Label2017-02-16
Letter2017-11-13
Label2017-11-14
Letter2019-10-17
Label2019-10-17

Application Sponsors

NDA 206843BRISTOL-MYERS SQUIBB

Marketing Status

Discontinued001
Discontinued002
Discontinued003

Application Products

001TABLET;ORALEQ 30MG BASE1DAKLINZADACLATASVIR DIHYDROCHLORIDE
002TABLET;ORALEQ 60MG BASE1DAKLINZADACLATASVIR DIHYDROCHLORIDE
003TABLET;ORALEQ 90MG BASE1DAKLINZADACLATASVIR DIHYDROCHLORIDE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2015-07-24PRIORITY
EFFICACY; EfficacySUPPL2AP2016-02-05PRIORITY
EFFICACY; EfficacySUPPL3AP2016-02-05PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL4AP2016-04-13PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL5AP2016-12-21STANDARD
LABELING; LabelingSUPPL6AP2017-02-14901 REQUIRED
LABELING; LabelingSUPPL7AP2017-11-09STANDARD
LABELING; LabelingSUPPL8AP2019-10-16STANDARD

Submissions Property Types

ORIG1Null7
SUPPL2Null15
SUPPL3Null6
SUPPL4Null0
SUPPL6Null7
SUPPL7Null15
SUPPL8Null15

CDER Filings

BRISTOL-MYERS SQUIBB
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 206843
            [companyName] => BRISTOL-MYERS SQUIBB
            [docInserts] => ["",""]
            [products] => [{"drugName":"DAKLINZA","activeIngredients":"DACLATASVIR DIHYDROCHLORIDE","strength":"EQ 30MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"Yes","rs":"No"},{"drugName":"DAKLINZA","activeIngredients":"DACLATASVIR DIHYDROCHLORIDE","strength":"EQ 60MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"Yes","rs":"No"},{"drugName":"DAKLINZA","activeIngredients":"DACLATASVIR DIHYDROCHLORIDE","strength":"EQ 90MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"Yes","rs":"No"}]
            [labels] => [{"actionDate":"10\/16\/2019","submission":"SUPPL-8","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/206843s008lbl.pdf\"}]","notes":""},{"actionDate":"11\/09\/2017","submission":"SUPPL-7","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/206843s007lbl.pdf\"}]","notes":""},{"actionDate":"02\/14\/2017","submission":"SUPPL-6","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/206843s006lbl.pdf\"}]","notes":""},{"actionDate":"02\/14\/2017","submission":"SUPPL-6","supplementCategories":"Labeling-Patient Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/206843s006lbl.pdf\"}]","notes":""},{"actionDate":"04\/13\/2016","submission":"SUPPL-4","supplementCategories":"Manufacturing (CMC)","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s004lbl.pdf\"}]","notes":"This supplement type does not usually require new labeling."},{"actionDate":"02\/05\/2016","submission":"SUPPL-3","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"}]","notes":""},{"actionDate":"02\/05\/2016","submission":"SUPPL-2","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"}]","notes":""},{"actionDate":"02\/05\/2016","submission":"SUPPL-1","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"}]","notes":""},{"actionDate":"07\/24\/2015","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/206843s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"07\/24\/2015","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/206843s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2015\\\/206843Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/206843Orig1s000TOC.cfm\"}]","notes":">"}]
            [supplements] => [{"actionDate":"10\/16\/2019","submission":"SUPPL-8","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/206843s008lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/206843Orig1s008ltr.pdf\"}]","notes":">"},{"actionDate":"11\/09\/2017","submission":"SUPPL-7","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/206843s007lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/206843Orig1s007ltr.pdf\"}]","notes":">"},{"actionDate":"02\/14\/2017","submission":"SUPPL-6","supplementCategories":"Labeling-Package Insert, Labeling-Patient Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/206843s006lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/206843Orig1s006ltr.pdf\"}]","notes":">"},{"actionDate":"12\/21\/2016","submission":"SUPPL-5","supplementCategories":"Manufacturing (CMC)","inserts":"[]","notes":"> Label is not available on this site."},{"actionDate":"04\/13\/2016","submission":"SUPPL-4","supplementCategories":"Manufacturing (CMC)","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s004lbl.pdf\"}]","notes":">"},{"actionDate":"02\/05\/2016","submission":"SUPPL-3","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/206843Orig1s003ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/206843Orig1s001,s003TOC.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"\"}]","notes":">"},{"actionDate":"02\/05\/2016","submission":"SUPPL-2","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/206843Orig1s002ltr.pdf\"}]","notes":">"},{"actionDate":"02\/05\/2016","submission":"SUPPL-1","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/206843s001s002s003lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/206843Orig1s001ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/206843Orig1s001,s003TOC.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"\"}]","notes":">"}]
            [actionDate] => 2019-10-16
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.